Free tool · No account
Clinical trials for kidney cancer
Kidney cancer (renal cell carcinoma) trials often combine immunotherapy with targeted drugs. Which fit depends on the subtype and whether the cancer has spread.
402 recruiting trials. Showing a sample.
- recruitingPhase 1, Phase 2NCT05765084
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of...
Listed by the study for Wilms Tumor. Record updated 2026-06-05.
Sponsored by University Hospital, AntwerpFull details on ClinicalTrials.gov → - recruitingNANCT07141225
Application of the "Off-Clamp And Sutureless" Technique in Robot-Assisted Partial Nephrectomy
The detection rate of renal masses smaller than 7 cm has significantly increased in recent years. To preserve postoperative renal function to the greatest extent possible, guidelines from the European Association of Urology (EAU), the National Comprehensive Cancer Network (NCC...
Listed by the study for Renal Cancer. Record updated 2025-09-05.
Sponsored by Shao PengfeiFull details on ClinicalTrials.gov → - recruitingNCT07299357
Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial
The study objective is to evaluate the use of Stereotactic Body Radiotherapy (high dose of radiation in a few fractions) to cure primary renal cancer in those patients that are not indicated to surgery (high risk of complications, refusal of the patient). This therapy is alrea...
Listed by the study for Renal Cancer. Record updated 2026-01-21.
Sponsored by Istituto Clinico HumanitasFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06005818
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
The goal of this Clinical Study is to understand the outcomes by informing therapy choice for adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease. The main question\[s\] it aims to answer are: * what is the progression free survival of a...
Listed by the study for Renal Cell Carcinoma. Record updated 2025-10-21.
Sponsored by University of Alabama at BirminghamFull details on ClinicalTrials.gov → - recruitingNANCT07714018
Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance
This clinical trial compares two different weight-loss programs, daily continuous calorie energy reduction (CER) versus (vs.) 5:2 intermittent fasting (IF), in preventing progression of kidney (renal) cancer among patients with one or more small renal masses (SRM) undergoing a...
Listed by the study for Renal Cell Carcinoma (RCC). Record updated 2026-08-20.
Sponsored by Roswell Park Cancer InstituteFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06376669
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
Listed by the study for Renal Cell Carcinoma. Record updated 2026-04-03.
Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsFull details on ClinicalTrials.gov → - recruitingPhase 4NCT07405086
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts...
Listed by the study for Advanced Renal Cell Carcinoma. Record updated 2026-06-12.
Sponsored by OHSU Knight Cancer InstituteFull details on ClinicalTrials.gov → - recruitingPhase 2NCT04981509
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts o...
Listed by the study for Hereditary Leiomyomatosis and Renal Cell Carcinoma. Record updated 2026-09-02.
Sponsored by National Cancer Institute (NCI)Full details on ClinicalTrials.gov → - recruitingPhase 3NCT03288532
Renal Adjuvant MultiPle Arm Randomised Trial
RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients with initially localised RCC develop metastatic disease following nephrectomy. Need fo...
Listed by the study for Renal Cell Carcinoma. Record updated 2020-09-07.
Sponsored by University College, LondonFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340...
Listed by the study for Carcinoma, Renal Cell. Record updated 2026-08-17.
Sponsored by Bristol-Myers SquibbFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-09-16. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this kidney cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.